![Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial - ScienceDirect Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0190962207014375-gr1.jpg)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial - ScienceDirect
![Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40259-020-00408-z/MediaObjects/40259_2020_408_Fig1_HTML.png)
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
![Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study | Annals of the Rheumatic Diseases Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study | Annals of the Rheumatic Diseases](https://ard.bmj.com/content/annrheumdis/74/2/389/F2.large.jpg)
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study | Annals of the Rheumatic Diseases
![Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4676ad7f-c189-43bf-9107-8362d2fe85ed/gr1.jpg)
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology
![Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet's disease: results from a large real-world observational study Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet's disease: results from a large real-world observational study](https://www.irjournal.org/upload//thumbnails/ir-2020-00013f7.jpg)
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet's disease: results from a large real-world observational study
![Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years - ACR Meeting Abstracts Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years - ACR Meeting Abstracts](https://acrabstracts.org/wp-content/uploads/2017/09/Paper_65902_abstract_95696_0.png)
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years - ACR Meeting Abstracts
![A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis | Arthritis Research & Therapy | Full Text A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-018-1676-y/MediaObjects/13075_2018_1676_Fig1_HTML.png)
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis | Arthritis Research & Therapy | Full Text
![Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results - Gastroenterology Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f57804e9-4fd5-4a24-8035-8f61a0ba5370/gr1.jpg)
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results - Gastroenterology
![Frontiers | Clinical Evaluation of Humira® Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics Frontiers | Clinical Evaluation of Humira® Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics](https://www.frontiersin.org/files/MyHome%20Article%20Library/221738/221738_Thumb_400.jpg)
Frontiers | Clinical Evaluation of Humira® Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics
![PDF) A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis PDF) A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis](https://i1.rgstatic.net/publication/327044672_A_comparative_clinical_study_of_PF-06410293_a_candidate_adalimumab_biosimilar_and_adalimumab_reference_product_HumiraR_in_the_treatment_of_active_rheumatoid_arthritis/links/5b74d65392851ca65063c619/largepreview.png)
PDF) A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
![Humira 40 mg/0.4 ml Pre-filled Syringe and Pre-filled Pen (Great Britain) - Summary of Product Characteristics (SmPC) - (emc) Humira 40 mg/0.4 ml Pre-filled Syringe and Pre-filled Pen (Great Britain) - Summary of Product Characteristics (SmPC) - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~31860~21~image1.png)
Humira 40 mg/0.4 ml Pre-filled Syringe and Pre-filled Pen (Great Britain) - Summary of Product Characteristics (SmPC) - (emc)
![Long-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy - American Journal of Ophthalmology Long-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy - American Journal of Ophthalmology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/e7d9672d-8e11-41a4-90df-21142e2c2cb9/gr1.jpg)
Long-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy - American Journal of Ophthalmology
![A randomised double-blind placebo-controlled crossover trial of HUMira ( adalimumab) for erosive hand OsteoaRthritis – the HUMOR trial - Osteoarthritis and Cartilage A randomised double-blind placebo-controlled crossover trial of HUMira ( adalimumab) for erosive hand OsteoaRthritis – the HUMOR trial - Osteoarthritis and Cartilage](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/10809fa6-e0a0-44f8-af74-63105af52771/gr1_lrg.jpg)
A randomised double-blind placebo-controlled crossover trial of HUMira ( adalimumab) for erosive hand OsteoaRthritis – the HUMOR trial - Osteoarthritis and Cartilage
![Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease - The Journal of Pediatrics Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease - The Journal of Pediatrics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0957c618-b55f-4945-a10b-7a282048ce2a/ympd10027-fig-0001_lrg.jpg)
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease - The Journal of Pediatrics
![Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial - The Lancet Gastroenterology & Hepatology Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial - The Lancet Gastroenterology & Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/c78e9483-7ac4-4166-9b04-05304211bdda/gr2.jpg)
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial - The Lancet Gastroenterology & Hepatology
![Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III - Ophthalmology Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III - Ophthalmology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/de00abc2-1d56-4cc2-86ae-7c1f823d1a0f/gr1.jpg)